Physician profile
Lan Wang
NPI 1306828447
$17,660.95
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,525 · 2020: $8,072 · 2021: $2,694 · 2022: $107 · 2023: $244 · 2024: $19.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17,071.37 | 2019-2023 | Lumakras |
| Foundation Medicine, INC. | $140.76 | 2023 | |
| Janssen Scientific Affairs, LLC | $62.75 | 2022-2023 | Erleada |
| E.R. Squibb & Sons, L.L.C. | $62.43 | 2020-2023 | Pomalyst |
| Celgene Corporation | $58.88 | 2020-2021 | |
| Genentech USA, INC. | $37.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.52 | 2023-2024 | Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $24.51 | 2022 | |
| Seagen INC. | $23.39 | 2019 | |
| Janssen Biotech, INC. | $19.88 | 2019 | |
| Genzyme Corporation | $19.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.24 | 2020 | |
| Haemonetics Corporation | $16.95 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $14.78 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.92 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $13.84 | 2020 | |
| Novocure INC. | $12.85 | 2021 | |
| Lilly USA, LLC | $11.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.